Top U.S. lawmaker seeks more Vytorin details
WASHINGTON |
WASHINGTON Feb 19 (Reuters) - The head of a U.S. House of Representatives panel is seeking additional documents from Merck and Co Inc (MRK.N) and Schering-Plough Corp SGP.N about clinical trials of controversial cholesterol drug Vytorin.
Energy and Commerce Committee Chairman Henry Waxman, in a letter to the two companies on Thursday, requested documents regarding monitoring boards aimed at overseeing patient safety in several clinical trials.
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters